Amrutanjan Relief Strong Pain Balm
Loading...Amrutanjan Relief Strong Pain Balm Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
There is currently no warning information available for this product. We apologize for any inconvenience.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin tablets USP and other antibacterial drugs, azithromycin tablets USP should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Azithromycin tablets USP are a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications [see Dosage and Administration (2)].
- •
- Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae.
- •
- Acute bacterial sinusitis due to Haemophilus influenzae, Moraxella catarrhalis. or Streptococcus pneumoniae.
- •
- Community-acquired pneumonia due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, or Streptococcus pneumoniae in patients appropriate for oral therapy.
- •
- Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy.
- •
- Uncomplicated skin and skin structure infections due to Staphylococcus aureus, Streptococcus pyogenes, or Streptococcus agalactiae.
- •
- Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae.
- •
- Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established.
[see Use in Specific Populations (8.4) and Clinical Studies (14.2)]
- •
- Acute otitis media (> 6 months of age) caused by Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae
- •
- Community-acquired pneumonia (> 6 months of age) due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumonia, or Streptococcus pneumoniae in patients appropriate for oral therapy.
- •
- Pharyngitis/tonsillitis (> 2 years of age) caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy.
Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following:
- •
- patients with cystic fibrosis,
- •
- patients with nosocomial infections,
- •
- patients with known or suspected bacteremia,
- •
- patients requiring hospitalization,
- •
- elderly or debilitated patients, or
- •
- patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia).
History
There is currently no drug history available for this drug.
Other Information
Azithromycin tablets USP contain the active ingredient azithromycin, USP, a macrolide antibacterial drug, for oral administration. Azithromycin, USP has the chemical name (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl) oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one. Azithromycin, USP is derived from erythromycin; however, it differs chemically from erythromycin in that a methyl-substituted nitrogen atom is incorporated into the lactone ring.
Azithromycin, USP has the following structural formula:
C38H72N2O12 M.W. 749
Azithromycin, USP, as the monohydrate, is a white crystalline powder with a molecular formula of C38H72N2O12•H2O and a molecular weight of 767.
Azithromycin tablets USP are supplied for oral administration as tablets containing azithromycin monohydrate equivalent to either 250 mg or 500 mg azithromycin, USP and the following inactive ingredients: corn starch, dibasic calcium phosphate anhydrous, croscarmellose sodium, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, sodium citrate, sodium lauryl sulfate, and titanium dioxide.
The 500 mg tablets also contain FD&C blue #2.
Sources
Amrutanjan Relief Strong Pain Balm Manufacturers
-
Amrutanjan Health Care Limited
![Amrutanjan Relief Strong Pain Balm (Menthol, Methyl Salicylate) Ointment [Amrutanjan Health Care Limited]](/wp-content/themes/bootstrap/assets/img/loading2.gif)
Amrutanjan Relief Strong Pain Balm | Preferred Pharmaceuticals, Inc.
2.1 Adult Patients[See Indications and Usage (1.1) and Clinical Pharmacology (12.3)]
Infection*
Recommended Dose/Duration of Therapy
Community-acquired pneumonia Pharyngitis/tonsillitis (second-line therapy) Skin/skin structure (uncomplicated)
500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5
Acute bacterial exacerbations of chronic obstructive pulmonary disease
500 mg once daily for 3 days
OR
500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5
Acute bacterial sinusitis
500 mg-once daily for 3 days
Genital ulcer disease (chancroid)
One single 1 gram dose
Non-gonococcal urethritis and cervicitis
One single 1 gram dose
Gonococcal urethritis and cervicitis
One single 2 gram dose
*DUE TO THE INDICATED ORGANISMS [see Indications and Usage (1.1)]
Azithromycin tablets can be taken with or without food.
2.2 Pediatric Patients1Infection*
Recommended Dose/Duration of Therapy
Acute otitis media
30 mg/kg as a single dose or 10 mg/kg once daily for 3 days or 10 mg/kg as a single dose on Day 1 followed by 5 mg/kg/day on Days 2 through 5.
Acute bacterial sinusitis
10 mg/kg once daily for 3 days.
Community-acquired pneumonia
10 mg/kg as a single dose on Day 1 followed by 5 mg/kg once daily on Days 2 through 5.
Pharyngitis/tonsillitis
12 mg/kg once daily for 5 days.
*DUE TO THE INDICATED ORGANISMS [see Indications and Usage (1.2)]
1 see dosing tables below for maximum doses evaluated by indication
Azithromycin for oral suspension can be taken with or without food.
PEDIATRIC DOSAGE GUIDELINES FOR OTITIS MEDIA, ACUTE BACTERIAL SINUSITIS, AND COMMUNITY-ACQUIRED PNEUMONIA
(Age 6 months and above, [see Use in Specific Populations (8.4)])
Based on Body Weight
OTITIS MEDIA AND COMMUNITY-ACQUIRED PNEUMONIA: (5 Day Regimen)*
Dosing Calculated on 10 mg/kg/day Day 1and 5 mg/kg/day Days 2 to 5.
Weight
100 mg/5 mL
200 mg/5 mL
Total mL perTreatmentCourse
Total mg perTreatmentCourse
Kg
Lbs.
Day 1
Days 2 to 5
Day 1
Days 2 to 5
5
11
2.5 mL (½ tsp)
1.25 mL (¼ tsp)
7.5 mL
150 mg
10
22
5 mL (1 tsp)
2.5 mL (½ tsp)
15 mL
300 mg
20
44
5 mL (1 tsp)
2.5 mL
(½ tsp)15 mL
600 mg
30
66
7.5 mL (1½ tsp)
3.75 mL
(¾ tsp)22.5 mL
900 mg
40
88
10 mL
(2 tsp)5 mL
(1 tsp)30 mL
1200 mg
50 and above
110 and above
12.5 mL (2½ tsp)
6.25 mL (1¼ tsp)
37.5 mL
1500 mg
* Effectiveness of the 3 day or 1 day regimen in pediatric patients with community-acquired pneumonia has not been established.
OTITIS MEDIA AND ACUTE BACTERIAL SINUSITIS: (3 Day Regimen)*
Dosing Calculated on 10 mg/kg/day
Weight
100 mg/5 mL
200 mg/5 mL
Total mL perTreatmentCourse
Total mg perTreatmentCourse
Kg
Lbs.
Days 1 to 3
Days 1 to 3
5
11
2.5 mL
(½ tsp)7.5 mL
150 mg
10
22
5 mL
(1 tsp)15 mL
300 mg
20
44
5 mL
(1 tsp)
15 mL
600 mg
30
66
7.5 mL
(1 ½ tsp)
22.5 mL
900 mg
40
88
10 mL
(2 tsp)
30 mL
1200 mg
50 and above
110 and above
12.5 mL
(2 ½ tsp)
37.5 mL
1500 mg
*Effectiveness of the 5 day or 1 day regimen in pediatric patients with acute bacterial sinusitis has not been established.
OTITIS MEDIA: (1 Day Regimen)
Dosing Calculated on 30 mg/kg as a single dose
Weight
200 mg/5 mL
Total mL perTreatment Course
Total mg perTreatment Course
Kg
Lbs.
1 Day Regimen
5
11
3.75 mL
(3/4 tsp)
3.75 mL
150 mg
10
22
7.5 mL
(1 ½ tsp)
7.5 mL
300 mg
20
44
15 mL
(3 tsp)
15 mL
600 mg
30
66
22.5 mL
(4 ½ tsp)
22.5 mL
900 mg
40
88
30 mL
(6 tsp)
30 mL
1200 mg
50 and above
110 and above
37.5 mL
(7 ½ tsp)
37.5 mL
1500 mg
The safety of re-dosing azithromycin in pediatric patients who vomit after receiving 30 mg/kg as a single dose has not been established. In clinical studies involving 487 patients with acute otitis media given a single 30 mg/kg dose of azithromycin, eight patients who vomited within 30 minutes of dosing were re-dosed at the same total dose.
Pharyngitis/Tonsillitis: The recommended dose of azithromycin for children with pharyngitis/tonsillitis is 12 mg/kg once daily for 5 days. (See chart below.)
PEDIATRIC DOSAGE GUIDELINES FOR PHARYNGITIS/TONSILLITIS
(Age 2 years and above, [see Use in Specific Populations (8.4)])
Based on Body Weight
PHARYNGITIS/TONSILLITIS: (5 Day Regimen)
Dosing Calculated on 12 mg/kg/day for 5 days.
Weight
200 mg/5 mL
Total mL per TreatmentCourse
Total mg per TreatmentCourse
Kg
Lbs.
Day 1 to 5
8
18
2.5 mL
(½ tsp)
12.5 mL
500 mg
17
37
5 mL
(1 tsp)
25 mL
1000 mg
25
55
7.5 mL
(1½ tsp)
37.5 mL
1500 mg
33
73
10 mL
(2 tsp)
50 mL
2000 mg
40
88
12.5 mL
(2½ tsp)
62.5 mL
2500 mg
Login To Your Free Account